Collectively, these results determined the minimum concentration of ACY-957 and ACY-1044 required to inhibit HDAC1,2 or HDAC3 activities in vivo in DLBCL cells. This evidence concerns the gene HDAC3 and diffuse large B-cell lymphoma.